Perlara
ActivePerlara: building the YC for rare disease parents
What it does
Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by selectively spinning out asset-centric clinical development NewCos. Perlara 1.5 (March 2019 - April 2020) was the transition to a one-person virtual clinical development company and when the epalrestat and aripiprazole repurposing trials were launched at Mayo Clinic for the treatment of PMM2-CDG and NGLY1-CDDG, respectively. Perlara 2.0 (May 2020 --> The first decentralized and distributed biotech
Its site says now · captured 2026-08-23
Perlara | Accelerating Therapies for Rare Disease Patients
Perlara partners with patients, researchers, and biotech innovators to accelerate treatments for rare metabolic diseases using AI-driven translational science.
Next to it in Healthcare and bio · rare disease drug discovery platform
- Numerion LabsY Combinator W15
Artificial intelligence for drug discovery.
- Pragma Bio (former VastBiome)Plug and Play
Mining the microbiome for novel products with therapeutic effect
- Silene BiotechTechstars TS 2017
silenebiotech.com
- Synkrino BiotherapeuticsY Combinator S18
Synkrino's AI, SATIS is a powerful, unbiased discovery system for…
- GEn1E LifesciencesY Combinator S19
AI platform accelerating therapies for rare & inflammatory diseases.
- zPREDICTAY Combinator S15
Patient-derived 3D tissue reconstruction models for preclinical…
- CardiaTec BiosciencesPlug and Play
CardiaTec is a digital biotechnology venture combining the power of AI and expert talent to redesign cardiovascular drug discovery.
- Crafton Biotechnology株式会社Plug and Play
Crafton Biotechnology Co. is a manufacturing company that researches, develops, and sells pharmaceutical products.